C-反应蛋白在肾癌预后评价中的意义  

The value of C-reactive protein in the evaluation of the prognosis of renal cancer

作　　者：蒋光亮[1] 胡青峰[1] 徐可[1] 

机构地区：[1]复旦大学附属华山医院泌尿外科,上海200040

出　　处：《国际肿瘤学杂志》2014年第5期361-363,共3页Journal of International Oncology

摘　　要：越来越多的证据显示炎症在肿瘤发生发展过程中扮演了极其重要的角色.C-反应蛋白（CRP）作为最具代表性的炎症反应指标,被认为与肾癌等多种肿瘤的预后密切相关.许多研究表明,CRP可以为实施手术、细胞因子治疗和分子靶向治疗的肾癌患者提供有价值的预后信息,并且已有预后模型将CRP纳入其中应用于患者的预后评估.Increasing evidence has proved that inflammation plays an extremely important role in tumorigenesis.As the most representative biomarker for inflammation,C-reactive protein （CRP） has been considered to be critically associated with the prognosis of a variety of malignant tumors,like renal cancer.Numerous studies have shown that CRP is a significant prognostic factor for renal cancer patients treated with surgery,cytokine therapy or molecular-targeted therapy,and CRP has been incorporated into some prognostic algorithms for renal cancer.

关 键 词：肾肿瘤 炎症 C反应蛋白质 预后 

分 类 号：R737.11[医药卫生—肿瘤]